Market-Moving News for May 30th
$AI
$CADL
$ONMD
Computer Software: Prepackaged Software
Technology
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $AI alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/28/2025 | $15.00 | Overweight | Stephens | |
| 9/3/2025 | $7.00 | Buy → Neutral | BofA Securities | |
| 8/13/2025 | Outperform → Perform | Oppenheimer | ||
| 8/12/2025 | $17.00 | Outperform → Market Perform | Northland Capital | |
| 8/11/2025 | $13.00 | Neutral → Underperform | DA Davidson | |
| 6/30/2025 | $23.00 | Buy | H.C. Wainwright | |
| 2/20/2025 | $25.00 | Buy | Citigroup | |
| 2/19/2025 | $20.00 | Buy | Canaccord Genuity |
4 - OneMedNet Corp (0001849380) (Issuer)
4 - OneMedNet Corp (0001849380) (Issuer)
4 - OneMedNet Corp (0001849380) (Issuer)
144 - C3.ai, Inc. (0001577526) (Subject)
8-K - OneMedNet Corp (0001849380) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
4 - C3.ai, Inc. (0001577526) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00
BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00
Oppenheimer downgraded C3.ai from Outperform to Perform
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company's common stock, with a per share exercise price of $5.84. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. Thi
MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans. Scaida BrainCT-ICH leverages artificial intelligence to analyze head CT images and identify suspected intracranial hemorrhage in approximately 5.97 seconds after image acquisition, enabling faster clinical tria
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G/A - C3.ai, Inc. (0001577526) (Subject)
SC 13G - OneMedNet Corp (0001849380) (Subject)
C3 AI (NYSE:AI), the Enterprise AI application software company, today announced the appointment of Mike Clayville to its board of directors, effective November 9, 2025. Mr. Clayville brings over 30 years of enterprise software and cloud infrastructure expertise. Most recently, he served as Chief Customer Officer at Stripe. Before Stripe, he led global commercial sales at Amazon Web Services, overseeing operations serving millions of customers across 170 countries. Earlier in his career, Mr. Clayville held senior leadership roles at VMware, BEA Systems, Tivoli Systems, and IBM, leading large-scale digital transformation initiatives. "Mike has spent his career helping companies grow an
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311
Siebel to continue as Executive Chairman C3 AI (NYSE:AI), the Enterprise AI application software company, today announced that Stephen Ehikian has been appointed Chief Executive Officer of C3 AI, effective September 1, 2025. Mr. Ehikian is a recognized innovator in the enterprise software industry and most recently served as Acting Administrator of the U.S. General Services Administration (GSA). Thomas M. Siebel will continue to serve as Executive Chairman. "I am honored to join C3 AI at such a pivotal time in the AI era," said Stephen Ehikian, CEO, C3 AI. "C3 AI is one of the most important companies in the AI landscape and enterprise software, with a platform and applications that are
Revenue increases 7% QoQ as Federal bookings grow 89%YoY C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE:AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2025. "We delivered a solid quarter driven by excellent performance in our Federal business and increased high-value deal activity across our customer base. The Federal market continues to be a large growth vector for us," said Stephen Ehikian, CEO, C3 AI. "Both Federal and commercial customers want to move faster, scale sooner, and embed AI as a core operating capability that delivers measurable economic value — and our platform is built for this m
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings: $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu
C3 AI (NYSE:AI), the Enterprise AI application software company, today announced it will issue its financial results for the fiscal second quarter, which ended October 31, 2025, following the close of the U.S. markets on Wednesday, December 3, 2025. C3 AI will host a conference call and webcast to discuss the financial results. The conference call will begin at 2:00 p.m. PST / 5:00 p.m. EST on December 3, 2025. Analysts and investors may participate in the question-and-answer session. Conference Call Details Date: Wednesday, December 3, 2025. Time: 2:00 p.m. Pacific Standard Time To access the conference call via a dial-in number and personalized PIN code, participants should register h